ArticleCancer discovery2024

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.

Andreas Varkaris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.